文献速递白血病

评估急性髓系白血病中的可测量残留病

Evaluating measurable residual disease in acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2018-01-01

综述指出,可测量残留病(MRD)是急性髓系白血病患者复发风险增高和生存期缩短的强独立预后标志,可用于细化风险分层和疗效评估。本文探讨MRD检测方法、临床实践挑战及欧洲白血病网MRD工作组的最新推荐,并指出将MRD纳入未来随机临床试验终点有助于标准化检测和更准确评估疗效。

要点

  • MRD定义为治疗后白血病细胞持续存在且低于形态学检测水平,是复发风险增高和生存期缩短的强独立预后标志。
  • MRD检测可能通过识别高危患者来指导缓解后治疗策略,该策略尚待正式验证。
  • 欧洲白血病网MRD工作组已发布急性髓系白血病MRD检测的最新推荐。

核心结论

  • MRD是急性髓系白血病患者复发风险增高和生存期缩短的强独立预后标志,可细化风险分层和疗效评估。
  • 基于MRD与复发风险的关联,推测治疗后MRD检测可能通过识别可从抢先治疗中获益的高危患者来指导缓解后治疗策略,但该策略尚待正式验证。
  • 将MRD纳入未来随机临床试验终点将提供标准化MRD检测所需数据,并可能比当前形态学指标更准确评估疗效。

研究设计与样本

  • 本文为综述,审视当前MRD检测方法、在常规临床实践中采用MRD检测的挑战以及欧洲白血病网MRD工作组发布的最新推荐。

主要发现

  • MRD定义为治疗后白血病细胞持续存在且低于形态学检测水平。
  • MRD与复发风险相关,但基于MRD检测指导缓解后治疗策略尚待正式验证。
  • 在可特异性清除MRD的药物可及的情况下,该策略可能特别有吸引力。

关键数值与推荐

  • 欧洲白血病网MRD工作组已发布急性髓系白血病MRD检测的最新推荐。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mounting evidence indicates that the presence of measurable ("minimal") residual disease (MRD), defined as posttherapy persistence of leukemic cells at levels below morphologic detection, is a strong, independent prognostic marker of increased risk of relapse and shorter survival in patients with acute myeloid leukemia (AML) and can be used to refine risk-stratification and treatment response assessment. Because of the association between MRD and relapse risk, it has been postulated that testing for MRD posttreatment may help guide postremission treatment strategies by identifying high-risk patients who might benefit from preemptive treatment. This strategy, which remains to be formally tested, may be particularly attractive with availability of agents that could be used to specifically eradicate MRD. This review examines current methods of MRD detection, challenges to adopting MRD testing in routine clinical practice, and recent recommendations for MRD testing in AML issued by the European LeukemiaNet MRD Working Party. Inclusion of MRD as an end point in future randomized clinical trials will provide the data needed to move toward standardizing MRD assays and may provide a more accurate assessment of therapeutic efficacy than current morphologic measures.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ravandi F, Walter RB, Freeman SD, et al. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018. PMID: 29895626. doi:10.1182/bloodadvances.2018016378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。